1-19 of 19
Jingjin Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Evaluation of Baseline CAR-Hematotox Scores to Predict Increased Severe Infection Risk in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Odronextamab

Matthew Matasar, David Tucker, Tae Min Kim, Stefano Luminari, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry
Journal: Blood
Blood (2024) 144 (Supplement 1): 1650.
https://doi.org/10.1182/blood-2024-200166
Published: 2024
Journal Articles

Evaluation of CAR-Hematotox Scoring As a Predictor of Infection Risk Following Treatment with Odronextamab (a CD20×CD3 Bispecific Antibody) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matthew Matasar, David Tucker, Tae Min Kim, Stefano Luminari, Yuan Cheng, Jingjin Li, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry
Journal: Blood
Blood (2024) 144 (Supplement 1): 3076.
https://doi.org/10.1182/blood-2024-200259
Published: 2024
Journal Articles

Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab

Gottfried von Keudell, Eliza A. Hawkes, Cecilia Carpio, Max S. Topp, Biyi Shen, Jingjin Li, Claire Hearnden, Saleem Shariff, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry, Sabarish Ayyappan
Journal: Blood
Blood (2024) 144 (Supplement 1): 3080.
https://doi.org/10.1182/blood-2024-200623
Published: 2024
Journal Articles

Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Sabarish Ayyappan, Won Seog Kim, Tae Min Kim, Jan Walewski, Seok-Goo Cho, Isidro Jarque, Elzbieta Iskierka-Jazdzewska, Michelle Poon, Sung Yong Oh, Francesca Lorraine Wei Inng Lim, Cecilia Carpio, Tran-Der Tan, Antonio Gutiérrez, Huilai Zhang, Junning Cao, Mingzhi Zhang, Benoit Tessoulin, Jingjin Li, Melanie Ufkin, Saleem Shariff, Lei Chi, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, H. Miles Prince
Journal: Blood
Blood (2023) 142 (Supplement 1): 436.
https://doi.org/10.1182/blood-2023-179818
Published: 2023
Journal Articles

Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study

Elzbieta Iskierka-Jazdzewska, Won Seog Kim, Seok-Goo Cho, Tae Min Kim, Isidro Jarque, Tadeusz Robak, Michelle Poon, H. Miles Prince, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran-Der Tan, Sabarish Ayyappan, Antonio Gutiérrez, Huilai Zhang, Junning Cao, Mingzhi Zhang, Benoit Tessoulin, Jingjin Li, Cristina Ivanescu, Matthew Reaney, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, James Harnett, Lei Chi, Jan Walewski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4504.
https://doi.org/10.1182/blood-2023-180743
Published: 2023
Journal Articles

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Won-Seog Kim, Tae Min Kim, Seok-Goo Cho, Isidro Jarque, Elżbieta Iskierka-Jażdżewska, Michelle Limei Poon, H. Miles Prince, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran-Der Tan, Sabarish Ayyappan, Antonio Gutierrez, Jingjin Li, Melanie Ufkin, Min Zhu, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, Jan Walewski
Journal: Blood
Blood (2022) 140 (Supplement 1): 1070–1071.
https://doi.org/10.1182/blood-2022-158406
Published: 2022
Journal Articles

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Tae Min Kim, MD PhD, Arancha Alonso, MD, Miles Prince, MD, Michal Taszner, MD, Seok-Goo Cho, MD, PhD, Don A. Stevens, MD, Michelle Poon, MD, Francesca Lim, MBBS, BSc, MRCP (UK), Steven Le Gouill, MD PhD, Cecilia Carpio, MD, Mary-Margaret Keating, MD FRCPC, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ayesha Sabir, BSc, Jingjin Li, PhD, Vladimir Jankovic, MD, Min Zhu, PhD, Jurriaan Brouwer-Visser, PhD, Siyang Leng, MD MS, L. Andres Sirulnik, MD PhD, Aafia Chaudhry, MD MBA, MS, Srikanth R. Ambati, MBBS, MD, Kim Won Seog, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-136344
Published: 2020
Journal Articles

Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy

Rajat Bannerji, MDPhD, John N. Allan, MD, Jon E. Arnason, MD, Jennifer R. Brown, MD PhD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Susan M. O'Brien, MD, Johannes Duell, MD, Peter Martin, FRCPC, MD MS, Robin M. Joyce, MD, Jingjin Li, PhD, Dina M. Flink, PhD, Min Zhu, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Andres Sirulnik, MD PhD, Aafia Chaudhry, MD MBA, MS, Srikanth R. Ambati, MBBS, MD, Max S. Topp, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-136659
Published: 2020
Journal Articles

REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Deepu Madduri, MD, Ashley Rosko, MD, Jason Brayer, PhDMD, Jeffrey Zonder, William I. Bensinger, MD, Jingjin Li, PhD, Linzhi Xu, PhD, Lieve Adriaens, PharmD, Dhruti Chokshi, BS, Weijiang Zhang, PhD, Anita Boyapati, PhD, Manish Sharma, MD, Frank Seebach, MD, L. Andres Sirulnik, MD PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Madhav V. Dhodapkar, MD, Suzanne Lentzsch, MD PhD, Dennis Cooper, MD, Sundar Jagannath, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-139192
Published: 2020
Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Rajat Bannerji, MD PhD, John N. Allan, MD, Jon E. Arnason, MD, Jennifer R. Brown, MD PhD, Ranjana H Advani, MD, Jeffrey A. Barnes, MD PhD, Stephen M Ansell, MD PhD, Susan M. O'Brien, MD, Julio Chavez, Johannes Duell, MD, Kevin A. David, MD, Peter Martin, FRCPC, MD MS, Robin M. Joyce, MD, Robert Charnas, PhD, Srikanth R. Ambati, MBBS, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Min Zhu, PhD, Jingjin Li, PhD, Peter Gasparini, MS, Anfal Ibrahim, BS, Vladimir Jankovic, MD, Nathalie Fiaschi, PhD, Olulanu Aina, PhD, Wen Zhang, PhD, Raquel P. Deering, PhD, Sara Hamon, PhD, Gavin Thurston, PhD, Andrew J. Murphy, PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Max S. Topp, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 762.
https://doi.org/10.1182/blood-2019-122451
Published: 2019
Journal Articles

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Max S. Topp, MD, Johannes Duell, MD, Jingjin Li, PhD, Vladimir Jankovic, MD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Lieve Adriaens, PharmD, Mary Peterman, PharmD, Srikanth R. Ambati, MBBS, MD, Rajat Bannerji, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4007.
https://doi.org/10.1182/blood-2019-126670
Published: 2019
Journal Articles

Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Dennis Cooper, MD, Deepu Madduri, MD, Suzanne Lentzsch, MD PhD, Sundar Jagannath, Jingjin Li, PhD, Anita Boyapati, PhD, Lieve Adriaens, PharmD, Dhruti Chokshi, BS, Min Zhu, PhD, Israel Lowy, MD PhD, David M. Weinreich, MD, George D. Yancopoulos, MD PhD, Manish Sharma, MD, Maria Karasarides, PhD, David Sternberg, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3176.
https://doi.org/10.1182/blood-2019-126818
Published: 2019
Journal Articles

Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes

Rajat Bannerji, MDPhD, Jon E. Arnason, MD, Ranjana Advani, MD, Jennifer R. Brown, MD PhD, John N. Allan, MD, Stephen M. Ansell, MD PhD, Jeffrey Barnes, MD PhD, Susan M. O'Brien, MD, Julio C. Chavez, MD, Johannes Duell, MD, Israel Lowy, MD PhD, Robert Charnas, PhD, David Sternberg, MD PhD, Srikanth Ambati, MBBS, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Xiaoyu Yan, PhD, Jingjin Li, PhD, Mark Navarro, BA, Peter Gasparini, MS, Vladimir Jankovic, MD, Nathalie Fiaschi, PhD, Wen Zhang, PhD, Sara Hamon, PhD, Gavin Thurston, PhD, Max S. Topp
Journal: Blood
Blood (2018) 132 (Supplement 1): 1690.
https://doi.org/10.1182/blood-2018-99-113328
Published: 2018
Journal Articles

Continued Treatment with Ruxolitinib Provides Additional Hematocrit Control and Spleen Volume Responses in Patients with PV Treated in the RESPONSE Study

Jean-Jacques Kiladjian, MD PhD, Tamás Masszi, MD PhD, Mark M. Jones, MD, Brian Gadbaw, MD, Jingjin Li, PhD, Dany Habr, MD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2804.
https://doi.org/10.1182/blood.V126.23.2804.2804
Published: 2015
Journal Articles

Changes in Quality of Life and Disease-Related Symptoms in Patients with Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results

Ruben Mesa, MD, Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N. Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Shui He, PhD, Mark M Jones, MD, Shreekant Parasuraman, PhD, Jingjin Li, PhD, Isabelle Côté, MD, Dany Habr, MD, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2014) 124 (21): 709.
https://doi.org/10.1182/blood.V124.21.709.709
Published: 2014
Journal Articles

Ruxolitinib Efficacy By Hematocrit Control in Patients with Polycythemia Vera: An Analysis of the RESPONSE Trial

Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Ruben Mesa, MD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2014) 124 (21): 3201.
https://doi.org/10.1182/blood.V124.21.3201.3201
Published: 2014
Journal Articles

Clinical Benefit of Ruxolitinib Treatment after Crossover from Best Available Therapy in Patients with Polycythemia Vera: Analysis of the RESPONSE Trial

Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Martin Griesshammer, MD, Tamas Masszi, MD PhD, Simon Durrant, MD, Francesco Passamonti, MD, Claire N Harrison, DM, FRCP, FRCPath, Fabrizio Pane, MD, Pierre Zachee, MD PhD, Ruben Mesa, MD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3181.
https://doi.org/10.1182/blood.V124.21.3181.3181
Published: 2014
Journal Articles

Efficacy of Ruxolitinib By Baseline Spleen Volume in Patients with Polycythemia Vera Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD, Mark M Jones, MD, Shui He, PhD, Jingjin Li, PhD, Dany Habr, MD, Jean-Jacques Kiladjian, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1840.
https://doi.org/10.1182/blood.V124.21.1840.1840
Published: 2014
Journal Articles

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD, PhD, Martin Griesshammer, Prof. Dr. med., Tamás Masszi, MD, PhD, Simon Durrant, MBBS, FRCP, FRCPath, Pierre Zachee, MD, PhD, Fabrizio Pane, MD, Claire N Harrison, DM, FRCP, FRCPath, Shui He, PhD, Lance Leopold, MD, Jingjin Li, Ulrich Pirron, PhD, Tomasz Lawniczek, MD, PhD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4071.
https://doi.org/10.1182/blood.V122.21.4071.4071
Published: 2013